Fundraising FoxCryptoMedix
Harpswell, US · Founded 2013 · Delaware corporation
Find your way into CryptoMedix
Sign up to see every warm intro you have to CryptoMedix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CryptoMedix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CryptoMedix Inc. is a pre-clinical biotech developing first-in-class therapeutic antibodies (CMX-101 and CMX-102) targeting the tumor microenvironment for immuno-oncology, promoting cytotoxic T-cell activity and interacting with immune checkpoints such as PD(L)1 and LAG-3. Its CMX-102 antibody is also positioned for use as antibody-drug conjugates and radionuclide conjugates targeting tumor cells.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$276.5K disclosed across 1 round · 2016
▶$276.5KraisedJun 2016 · 7 investors · BiotechnologyRule 506(b)
- Janet Yancey-WronaExecutive Officer, Director
- Bob DavisDirector
- Bernd SeizingerExecutive Officer, Director
- Leonard LiebesDirector
- Bob SuvaDirector
- Offering amount
- $500K
- Amount sold
- $276.5K
- Minimum investment
- $500
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as CryptoMedix.
Frequently asked questions
- What does CryptoMedix do?
- CryptoMedix Inc. is a pre-clinical biotech developing first-in-class therapeutic antibodies (CMX-101 and CMX-102) targeting the tumor microenvironment for immuno-oncology, promoting cytotoxic T-cell activity and interacting with immune checkpoints such as PD(L)1 and LAG-3. Its CMX-102 antibody is also positioned for use as antibody-drug conjugates and radionuclide conjugates targeting tumor cells.
- How much funding has CryptoMedix raised?
- CryptoMedix has disclosed $276.5K raised across 1 round.
- Where is CryptoMedix headquartered?
- CryptoMedix is headquartered in Harpswell, US.